BDX

Becton, Dickinson and Company (BDX) has gained 25.5% over six months, driven by successful portfolio realignment following its Life Sciences separation, strong earnings growth across high-growth platforms, and a major $19 billion U.S. manufacturing partnership agreement. The company raised its fiscal 2026 EPS guidance and returned $3.1 billion to shareholders, though it faces headwinds from tariffs, Alaris remediation, and China vaccine weakness.

Becton, Dickinson and Company (BD) announced positive nine-month results from the AGILITY trial for its Revello Vascular Covered Stent in treating iliac artery disease. The trial met its primary endpoint with a 2.8% failure rate, 97.2% primary patency, and 98.3% freedom from clinically driven target lesion revascularization.

The device remains investigational in the U.S. with clinical follow-up continuing through 36 months. The global iliac stent market is projected to grow at a 6.5% CAGR through 2033.

Becton Dickinson (BDX) has demonstrated a strong earnings-beat streak, with an average surprise of 3.78% over the last two quarters. The company currently has a positive Earnings ESP of +0.21% combined with a Zacks Rank #3 (Hold), suggesting another potential earnings beat in its November 5, 2026 report. Stocks with this combination historically beat consensus estimates nearly 70% of the time.

Becton, Dickinson and Company (BD) announced a landmark partnership with the U.S. Government to invest $19 billion in domestic manufacturing expansion, including $3 billion toward manufacturing capacity. The company aims to increase domestically supplied essential medical consumables to 80% and manufacture all U.S.-used needles domestically with American-made steel. The agreement provides tariff protection on covered products, though financial impact remains unquantified pending finalization of tariff rates and implementation timing.

The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, and technology adoption, with the global market expected to reach $318.77 billion by 2031. However, tariffs, commodity inflation, and policy-driven pricing changes present headwinds. Five key stocks—McKesson, Cardinal Health, Becton Dickinson, Merit Medical Systems, and ProDex—are highlighted as well-positioned to capitalize on favorable industry trends through 2026.

ResMed is set to report Q1 fiscal 2027 results on October 29, with revenues projected at $1.39 billion (up 4%) and EPS expected to rise 4.7% to $2.67. The Sleep and Breathing Health segment is anticipated to grow 6.4% driven by device demand and new product launches, while Residential Care Software revenues are expected to decline 12.7% following the September 2026 sale of MatrixCare to Frazier Healthcare Partners. The company has a Zacks Rank #3 with a negative Earnings ESP of -0.60%.

Danaher Corporation reported Q3 adjusted EPS of $2.11, beating estimates by 9.9%, with revenues of $6.55 billion in line with expectations. The company raised its 2026 adjusted EPS guidance to $8.57-$8.62 and expects 2.5% core revenue growth. Diagnostics segment sales jumped 17% driven by acquisitions, though respiratory testing revenues declined significantly from $500M to $350M year-over-year.

Catholic Medical Mission Board (CMMB) opened its new Distribution Center at the Brethren Service Center in New Windsor, Maryland on October 22, 2026. The relocation expands CMMB's operational capacity for its Access to Medicines Program, which distributed $243.5 million worth of medicines and medical supplies to 64 partners across 28 countries in 2025. The partnership strengthens both organizations' humanitarian efforts.

The global microbiology testing market is projected to grow from USD 6.3 billion in 2025 to USD 13.7 billion by 2034, driven by increasing infectious disease prevalence, antimicrobial resistance concerns, and stringent regulatory requirements. North America leads with 42% market share, while Asia-Pacific is expected to record the fastest growth. Key drivers include technological advancements in molecular diagnostics, laboratory automation, and expanding clinical diagnostic infrastructure.

The global liver cancer diagnostics market is projected to grow from USD 10.5 billion in 2025 to USD 19.8 billion by 2034, driven by rising hepatocellular carcinoma incidence, increasing chronic liver disease prevalence, and advances in diagnostic technologies including liquid biopsy, AI-assisted imaging, and blood-based biomarkers. North America leads the market with 41% share, while Asia-Pacific is expected to be the fastest-growing region.

The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, AI automation, and aging demographics. The global medical supplies market is expected to reach $318.77 billion by 2031 with a 10% CAGR.

However, tariffs, commodity inflation, and pharmaceutical pricing changes remain headwinds. Key industry players show mixed near-term prospects with the industry trading at favorable valuations compared to broader markets.